http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#Head http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#provenance http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#pubinfo http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion http://purl.obolibrary.org/obo/DOID_3908 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3908 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09035 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association http://www.w3.org/2000/01/rdf-schema#label opdivo is a programmed death receptor 1 pd 1 blocking antibody indicated for the treatment of 1 1 1 2 1 3 a 1 4 1 5 1 5 a 1 6 1 7 a 1 8 a 1 9 a 1 1 a opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of patients with unresectable or metastatic melanoma opdivo is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection opdivo is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving opdivo opdivo is indicated for the treatment of patients with metastatic small cell lung cancer sclc with progression after platinum based chemotherapy and at least one other line of therapy this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 4 opdivo in combination with ipilimumab is indicated for the treatment of patients with intermediate or poor risk previously untreated advanced rcc opdivo is indicated for the treatment of adult patients with classical hodgkin lymphoma chl that has relapsed or progressed after autologous hematopoietic stem cell transplantation hsct and brentuximab vedotin or 3 or more lines of systemic therapy that includes autologous hsct this indication is approved under accelerated approval based on overall response rate see clinical studies 14 6 opdivo is indicated for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck scchn with disease progression on or after platinum based therapy opdivo is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who this indication is approved under accelerated approval based on tumor response rate and duration of response see clinical studies 14 8 opdivo as a single agent or in combination with ipilimumab is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high msi h or mismatch repair deficient dmmr metastatic colorectal cancer crc that has progressed following treatment with a fluoropyrimidine oxaliplatin and irinotecan this indication is approved under accelerated approval based on overall response rate and duration of response see clinical studies 14 9 opdivo is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib this indication is approved under accelerated approval based on tumor response rate and durability of response see clinical studies 14 1 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09035 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#provenance http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#pubinfo http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig http://purl.org/nanopub/x/hasSignature FH3USB3QOaerGJmhx4XzZ2b28e0UBIIXQ0gXfqpfTG3WyAA85sGaiH6DahAGZiyUXgSjpOw6u6UZNYcOBzfuxftlF1oTZ5Kyc+ZPHjGTO0him3fJoQU//DIVmZQ+Pw0BtaWIf3SETNcMJFM1FF5IrBIrhOdhi/LgQI2gwQQWTQw= http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://purl.org/dc/terms/created 2021-07-03T15:33:18.413+02:00 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAZ3PbvqVK1rdlnvSXvhMLFhFI1b0IRmrHEjGaxOLsdQA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs